Hester Biosciences Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-20
Stock price
₹2523.40
Market cap
2,147 Cr
Stock P/E
43.4
P/B
5.84
Dividend yield
0.3%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 88 Cr | 158 Cr | 225 Cr | 305 Cr | 82 Cr | 166 Cr | 63 Cr | 82 Cr | 84 Cr | 71 Cr | 77 Cr | 100 Cr |
| Operating expenses (approx.) | 72 Cr | 125 Cr | 181 Cr | 240 Cr | 63 Cr | 126 Cr | 50 Cr | 70 Cr | 59 Cr | 50 Cr | 59 Cr | 66 Cr |
| EBITDA | 16 Cr | 33 Cr | 44 Cr | 64 Cr | 19 Cr | 40 Cr | 13 Cr | 12 Cr | 25 Cr | 21 Cr | 18 Cr | 34 Cr |
| OPM % | 17.7% | 20.9% | 19.6% | 21.1% | 22.9% | 24.0% | 20.4% | 14.9% | 29.9% | 30.2% | 23.8% | 34.2% |
| Other income | 1 Cr | 6 Cr | 6 Cr | 11 Cr | 1 Cr | 3 Cr | 8 Cr | -7 Cr | 2 Cr | 10 Cr | 0.67 Cr | -3 Cr |
| Interest | 3 Cr | 11 Cr | 13 Cr | 20 Cr | 5 Cr | 11 Cr | -4 Cr | 6 Cr | 2 Cr | 2 Cr | 2 Cr | 5 Cr |
| Depreciation | 5 Cr | 10 Cr | 13 Cr | 17 Cr | 4 Cr | 8 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 6 Cr |
| Profit before tax | 8 Cr | 13 Cr | 18 Cr | 27 Cr | 10 Cr | 21 Cr | 12 Cr | 2 Cr | 19 Cr | 15 Cr | 12 Cr | 23 Cr |
| Tax % | 29.2% | 38.6% | 40.7% | 39.4% | 31.9% | 31.9% | 15.8% | 90.5% | 15.1% | 18.2% | 34.5% | 36.8% |
| Net profit | 7 Cr | 11 Cr | 15 Cr | 21 Cr | 7 Cr | 16 Cr | 11 Cr | 2 Cr | 17 Cr | 14 Cr | 9 Cr | 17 Cr |
| EPS (₹) | ₹7.89 | ₹12.64 | ₹17.36 | ₹24.88 | ₹8.80 | ₹18.66 | ₹13.41 | ₹1.82 | ₹20.33 | ₹16.85 | ₹10.94 | ₹19.45 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 Cr | 183 Cr | 214 Cr | 235 Cr | 266 Cr | 305 Cr | 311 Cr | 333 Cr | Sign in for TTM |
| Operating expenses (approx.) | 103 Cr | 121 Cr | 144 Cr | 161 Cr | 215 Cr | 251 Cr | 246 Cr | 233 Cr | Sign in for TTM |
| EBITDA | 75 Cr | 62 Cr | 70 Cr | 74 Cr | 51 Cr | 54 Cr | 65 Cr | 99 Cr | Sign in for TTM |
| OPM % | 42.3% | 33.7% | 32.7% | 31.4% | 19.0% | 17.6% | 20.9% | 29.8% | Sign in for TTM |
| Other income | 7 Cr | 6 Cr | 5 Cr | 14 Cr | 15 Cr | 11 Cr | 4 Cr | 10 Cr | Sign in for TTM |
| Interest | 7 Cr | 7 Cr | 7 Cr | 4 Cr | 9 Cr | 20 Cr | 13 Cr | 11 Cr | Sign in for TTM |
| Depreciation | 12 Cr | 13 Cr | 13 Cr | 17 Cr | 21 Cr | 17 Cr | 17 Cr | 19 Cr | Sign in for TTM |
| Profit before tax | 57 Cr | 41 Cr | 50 Cr | 53 Cr | 36 Cr | 27 Cr | 35 Cr | 69 Cr | Sign in for TTM |
| Tax % | 28.4% | 25.0% | 30.7% | 26.4% | 33.9% | 39.4% | 30.3% | 26.4% | Sign in for TTM |
| Net profit | 41 Cr | 31 Cr | 35 Cr | 39 Cr | 28 Cr | 21 Cr | 29 Cr | 57 Cr | Sign in for TTM |
| EPS (₹) | ₹47.84 | ₹36.44 | ₹40.79 | ₹46.41 | ₹32.96 | ₹24.88 | ₹33.89 | ₹67.57 | Sign in for TTM |
| Dividend payout % | — | — | — | 21.5% | 30.3% | 32.2% | 17.9% | 10.5% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr |
| Reserves | 169 Cr | 193 Cr | 220 Cr | 251 Cr | 271 Cr | 283 Cr | 306 Cr | 352 Cr |
| Borrowings | — | — | — | — | 268 Cr | 239 Cr | 74 Cr | 98 Cr |
| Other liabilities | — | — | 183 Cr | 302 Cr | 113 Cr | 120 Cr | 252 Cr | 212 Cr |
| Total liabilities | — | — | 411 Cr | 562 Cr | 670 Cr | 662 Cr | 653 Cr | 678 Cr |
| Fixed assets (net) | — | — | — | — | 259 Cr | 239 Cr | 233 Cr | 411 Cr |
| CWIP | — | — | — | — | 146 Cr | 168 Cr | 177 Cr | 9 Cr |
| Investments | — | — | — | — | 25 Cr | 0.0000 Cr | 0.0000 Cr | 2 Cr |
| Other assets | — | — | — | — | 234 Cr | 220 Cr | 201 Cr | 209 Cr |
| Total assets | — | — | 411 Cr | 562 Cr | 670 Cr | 662 Cr | 653 Cr | 678 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 9 Cr | 24 Cr | 48 Cr | 65 Cr | 64 Cr |
| Cash from investing | — | — | — | -117 Cr | -77 Cr | -23 Cr | -19 Cr | -3 Cr |
| Cash from financing | — | — | — | 112 Cr | 42 Cr | -26 Cr | -52 Cr | -49 Cr |
| Net cash flow | — | — | — | 3 Cr | -12 Cr | -0.41 Cr | -7 Cr | -3 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -87 Cr | -54 Cr | 24 Cr | 44 Cr | 46 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 35.8% | 24.2% | 24.8% | 22.0% | 5.4% | 6.7% | 12.0% | 17.2% |
| ROE % | 23.4% | 14.5% | 15.1% | 15.1% | 9.2% | 6.2% | 8.4% | 15.1% |
| Debtor days | — | — | — | — | 109 | 94 | — | — |
| Inventory days | — | — | — | — | 583 | 508 | 401 | 374 |
| Days payable | — | — | — | — | 206 | 178 | — | — |
| Cash conversion cycle | — | — | — | — | 486 | 425 | 401 | 374 |
| Debt / equity | 0.00 | — | — | — | 0.96 | 0.82 | 0.23 | 0.27 |
| Current ratio | — | — | — | — | 1.53 | 2.03 | 1.56 | 1.37 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 5.04 | 4.22 | 1.06 | 0.96 |
Compare with peers
Loading peers…